Cargando…

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA

PURPOSE: Human papillomavirus (HPV) DNA offers a convenient circulating tumor DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital PCR (dPCR), provide insufficient accuracy for clinical applications in patients with low disease burden. We asked whether a next-gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Eric, Han, Kathy, Zou, Jinfeng, Zhao, Zhen, Zheng, Yangqiao, Wang, Ting Ting, Rostami, Ariana, Siu, Lillian L., Pugh, Trevor J., Bratman, Scott V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401563/ https://www.ncbi.nlm.nih.gov/pubmed/34580115 http://dx.doi.org/10.1158/1078-0432.CCR-19-2384

Ejemplares similares

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
por: Jeannot, Emmanuelle, et al.
Publicado: (2021)

A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization
por: Sastre-Garau, Xavier, et al.
Publicado: (2021)

DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
por: Tawk, Bouchra, et al.
Publicado: (2023)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
por: Madanat-Harjuoja, Laura M., et al.
Publicado: (2022)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients
por: Batool, Syeda Maheen, et al.
Publicado: (2022)

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
por: Henriksen, Tenna Vesterman, et al.
Publicado: (2022)

Oral lichen planus and HPV lesions
por: Casu, Cinzia, et al.
Publicado: (2018)

Koilocytes due to HPV in the urine sediment
por: Poloni, José Antonio Tesser, et al.
Publicado: (2020)

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
por: Chen, Xiaoji, et al.
Publicado: (2021)

Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands
por: Kwon, Daniel, et al.
Publicado: (2022)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
por: Compadre, Amanda J., et al.
Publicado: (2023)

Designing circulating tumor DNA-based interventional clinical trials in oncology
por: Araujo, Daniel V., et al.
Publicado: (2019)

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer
por: Chera, Bhishamjit S., et al.
Publicado: (2020)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
por: Cheema, Amrita K., et al.
Publicado: (2023)

Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
por: Salari, Keyan, et al.
Publicado: (2023)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
por: Shi, Zhen, et al.
Publicado: (2022)

High efficiency error suppression for accurate detection of low-frequency variants
por: Wang, Ting Ting, et al.
Publicado: (2019)

Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
por: Akturk, Guray, et al.
Publicado: (2021)

Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
por: Bidkar, Anil P., et al.
Publicado: (2023)

Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV‐related oropharyngeal cancer and cancer of unknown primary
por: Tanaka, Hidenori, et al.
Publicado: (2021)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
por: Meagher, Nicola S., et al.
Publicado: (2022)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
por: Larkin, James R., et al.
Publicado: (2022)

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
por: Fitzpatrick, Amanda, et al.
Publicado: (2022)

Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
por: Thorat, Mangesh A., et al.
Publicado: (2021)

Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC
por: Sahaf, Bita, et al.
Publicado: (2021)

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
por: Damrauer, Jeffrey S., et al.
Publicado: (2021)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
por: Sharma, Sai Kiran, et al.
Publicado: (2022)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
por: Marisa, Laetitia, et al.
Publicado: (2021)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022)

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
por: Li, Shuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bdhktpcnp9se8c3pdrcc4omqpm